Search

Considerations in the management of retinal disorders

Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...

Can thou lyse this? A national study of emergency canthotomy and cantholysis

Eighty-two-year old Janet Smith woke up on the floor. Had she been unconscious? Her head hurt. It was the middle of the night, but in the darkness she suddenly wasn’t sure whether she could see out of her right eye....

Inherited retinal disorders now the leading cause of blindness

The recent paper in BMJ Open, from the UCL Institute of Ophthalmology, ‘A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010’ concludes that inherited retinal disorders (IRD) such...

Advances and developments in medical retina

The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...

Management of DMO and PDR in 2019

An evidence-based approach to the management of diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR) in 2019 was outlined by Sobha Sivaprasad, UK, in presentations during the Diabetic Retina scientific session September 6 2019, at the 19th European Society...

Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease

Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

A life outside ophthalmology

Lloyd Paul Aiello. It was an absolute privilege to speak to Lloyd Paul Aiello, Professor of Ophthalmology, Harvard Medical School, and Vice President of Ophthalmology and Director, Beetham Eye Institute, Joslin Diabetes Center, USA. Prof Aiello is a third-generation ophthalmologist,...

Neuro-ophthalmology: the extended role of an orthoptist

Neuro-ophthalmology has always been a speciality of interest during my studies and now in my career. In 2018, I started a Band 7 post which gave me an extended role in neuro-ophthalmology and the responsibility of developing an orthoptic led...